ALSO NOTED: Ranbaxy recalls tainted Gebapentin;BMS gets Abilify on fast track for bipolar kids;

> After discovering impurities in the pills, Ranbaxy Laboratories is recalling 73 million tablets of its epilepsy remedy Gebapentin from the U.S. market. Report

> Bristol-Myers Squibb and partner Otsuka Pharmaceutical said the FDA will fast-track their application to market the antipsychotic Abilify for use in children with bipolar disorder. Report

> India's Orchid Chemicals & Pharmaceuticals got the FDA's nod for its version of the antibiotic Cefpodoxime Proxetil, marketed by Pfizer under the brand name Vantin. Report

> Surgical instruments maker Gyrus was hit with a patent infringement suit by rival ArthroCare. Report

And Finally... Governments meet next week to hammer out a flu-virus sharing agreement so scientists can better track the evolution of H5N1. Report

Suggested Articles

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.